Peptide appearance
Lyophilized form helps protect peptide quality. Peptides are supplied as a dry powder, which may look like a compact "puck" or a lighter powder inside the vial.
Because the peptide is dry, it does not require refrigerated shipping during normal transit, including warm seasonal conditions. For longer storage, follow the storage guidance in the product description.
Appearance can vary. The stated peptide content is checked through third-party analysis.
Read more in the product description.
Solution not bundled
Peptides are delivered as lyophilized powder. This dry form helps preserve peptide quality during storage and transport and does not require refrigerated shipping during normal transit.
To prepare a solution, use a solvent such as Bacteriostatic water. It is sold separately, so add it only when you need it for peptide preparation.
Read more in the product description.
Signalling peptide
BPC-157
In stock
BPC-157 is a synthetic peptide made of 15 amino acids. Published studies look at fibroblasts, extracellular matrix, blood-vessel signalling, and cell movement.
Order within — · ships Wed, 23 Sep Cutoff 10:00 · local time
Arrives Sep 28 - Sep 30 to Europe
More at checkout
BPC-157
51,50 €
BPC-157 reference peptide for tissue-signalling, gut-barrier, and repair-pathway models.
Research overview
BPC-157
BPC-157 is a defined 15-amino-acid peptide. Its sequence, form, and lot-specific test results should be checked directly.
Studies cover connective-tissue, vascular, cell-protection, and oxidative-stress models. They identify research questions but do not promise a result for this product.
Fibroblast and matrix models
Studies measure fibroblast activity, collagen, cell growth, re-epithelialisation, and ERK1/2 signalling in laboratory models. Each observation applies only to the system used in the paper.
Other studies look at tendon, muscle, ligament, and bone models, with a focus on cell movement and extracellular-matrix organisation.
Vascular and cell-protection questions
Published work also looks at endothelial cells, blood-vessel development, nitric-oxide signals, and oxidative stress. The original model and method are needed to understand each result.
Compound information
Specifications
Molecular profile
- Sequence
- Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
- Molecular mass
- 1419.54 g/mol
- CAS number
- 137525-51-0
- Molecular formula
- C62H98N16O22
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- Synthetic pentadecapeptide; supplied strictly for research use only.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Tests
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 10mg
99.5%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 12.45 mg
- PurityPeptide screening
- 99.5%
- Identity (FTIR)FTIR spectrum
- 997
- Identity (RT)Retention time
- 0.982
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Source record
References
National Center for Biotechnology Information
PubChem Compound Summary: BPC-157
Authoritative identity record for BPC-157.
PubChem · View source ↗Chang CH, Tsai WC, Lin MS, et al. · 2011
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Primary BPC-157 study in a defined experimental tendon model.
Journal of Applied Physiology · 10.1152/japplphysiol.00945.2010 View source ↗Krivic A, Anic T, Seiwerth S, et al. · 2006
Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation
Primary BPC-157 study in a defined rat tendon-to-bone model.
Journal of Orthopaedic Research · 10.1002/jor.20096 View source ↗Chemical Abstracts Service
CAS Common Chemistry: 137525-51-0
Authoritative CAS Registry Number record for BPC-157.
CAS Common Chemistry · View source ↗National Center for Biotechnology Information
PubChem compound record
PubChem · View source ↗Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM · 2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
HSS journal : the musculoskeletal journal of Hospital for Special Surgery · View source ↗Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, Zhang W, Wang S, Zhang K, He L, Zhang W, Zhang C, Hao Q, Zhang Y, Li M, Li W · 2020
Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds
Regulatory toxicology and pharmacology : RTP · View source ↗Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, Grgic T, Strbe S, Zukanovic G, Crvenkovic D, Madzarac G, Rukavina I, Sucic M, Baric M, Starcevic N, Krstonijevic Z, Bencic ML, Filipcic I, Rokotov DS, Vlainic J · 2016
Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Current neuropharmacology · View source ↗Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, Štrbe S, Zoričić Z, Filipčić I, Brečić P, Seiverth S, Sikirić P · 2022
Pentadecapeptide BPC 157 and the central nervous system
Neural regeneration research · View source ↗Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS · 2017
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Journal of molecular medicine (Berlin, Germany) · View source ↗Sebecić B, Nikolić V, Sikirić P, Seiwerth S, Sosa T, Patrlj L, Grabarević Z, Rucman R, Petek M, Konjevoda P, Jadrijević S, Perović D, Slaj M · 1999
Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation
Bone · View source ↗Lee E, Burgess K · 2025
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Alternative therapies in health and medicine · View source ↗· 2018
BPC-157 enhances growth hormone receptor expression in injured tendon tissueStaresinic M, Sebecic B, et al
Growth Hormone & IGF Research · View source ↗T. Huang et al. · 2015
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro
Drug Des. Devel. Ther ·Chung-Hsun Chang et al.
Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts
·3D. Drmic et al. · 2018
Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine
World J. Gastroenterol ·F. Amic et al. · 2018
Bypassing major venous occlusion and duodenal lesions in rats, and therapy with the stable gastric pentadecapeptide BPC 157, L-NAME and L-arginine
World J. Gastroenterol ·J. Vukojević et al. · 2018
Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157
Vascul. Pharmacol ·D. Drmic et al. · 2017
Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME
World J. Gastroenterol ·Z. Grabarevic et al. · 1997
The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks
J. Physiol. Paris ·P. Sikiric et al. · 1990
Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing
Curr. Pharm. Des ·S. Seiwerth et al. · 1972
BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing
Curr. Pharm. Des ·Y.-L. Hu et al. · 2014
FAK and paxillin dynamics at focal adhesions in the protrusions of migrating cells
Sci. Rep ·K. Škrlec et al. · 2018
Engineering recombinant Lactococcus lactis as a delivery vehicle for BPC-157 peptide with antioxidant activities
Appl. Microbiol. Biotechnol ·D. Strinic et al. · 2017
BPC 157 counteracts QTc prolongation induced by haloperidol, fluphenazine, clozapine, olanzapine, quetiapine, sulpiride, and metoclopramide in rats
Life Sci ·N. Jelovac et al. · 1999
Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats
Eur. J. Pharmacol ·Tlak Gajger, J. Ribarić, M. Smodiš Škerl, J. Vlainić, and P. Sikirić · 2018
Stable gastric pentadecapeptide BPC 157 in honeybee (Apis mellifera) therapy, to control Nosema ceranae invasions in apiary conditions
J. Vet. Pharmacol. Ther ·Customer reviews
Continue exploring
